Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

Name: Αlpha¹ Rigor Record — Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
Item: Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
Rating: 96
Author: Αlpha¹

Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 2 high issues for “Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsStatistic did not reproduce−0.5★
IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Reported statistics do not recomputeRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized trial with rigorous design, clear reporting of methods and results, and appropriate ethical approvals. The main weaknesses are the lack of an explicit data availability statement and minor reporting inconsistencies (e.g., CI bound discrepancy, blinding not explicitly stated).

Both reviewers agreed on all dimensions; no divergence. The study is an interventional trial; all non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 2 tests, one of which showed a minor p-value discrepancy; this does not affect the overall assessment.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 2 tests: 1 consistent, 1 inconsistent; 2 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior evidence on dMMR/MSI-H colon cancer, the role of immune checkpoint inhibitors, and the rationale for combining atezolizumab with FOLFOX. It acknowledges the resistance of dMMR tumors to fluoropyrimidines and the benefit of oxaliplatin. The hypothesis follows logically from the cited evidence. Limitations of prior work are implicitly addressed by the design of a randomized phase 3 trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

direct quote[Introduction, paragraph 1]

“In patients with metastatic dMMR colorectal cancer which encompasses those with microsatellite instability (MSI-H), the immune checkpoint inhibitor pembrolizumab was shown to be superior to fluoropyrimidine-based chemotherapy where it produced significantly longer progression-free survival with fewer adverse events as first-line therapy (KEYNOTE-177).”